Onco Wiki / Maladie

Carcinome de cellules squameuses et de la vulve

Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.

IDDIS-VULVAR-VAGINAL-SCC
TypeMaladie
Alias
CSC vulvar associé au VPHCSC dérivée du sclérose lichenCSC dérivée du VINCSC vaginalCSC de la population de la VulvarПлоскоклітинна карцинома вульви та піхви
Étatreviewed 2026-05-18 | pending_clinical_signoff
MaladiesAucune déclaration
SourcesSRC-IARC-MONO-100B-2012 SRC-NCCN-CERVICAL-2025

Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.

Source YAML

icd_o_3_morphology8070/3
icd_o_3_topography["C51", "C52"]
icd_10C51, C52
who_classificationWHO Female Genital Tumours 5th ed (2020): Vulvar SCC (HPV-associated + HPV-independent) and Vaginal SCC

Capacités

Notes

Two biological subgroups managed similarly anatomically but with distinct prevention implications: HPV-driven (vaccination prevents precursor lesions; screening with vulvar exam + biopsy of any persistent lesion) vs HPV-independent (lichen sclerosus surveillance is the dominant prevention modality; topical clobetasol may reduce malignant transformation in select cohorts). Treatment: early-stage — wide local excision ± inguinal sentinel node biopsy (GROINSS-V paradigm replacing routine complete inguinofemoral lymphadenectomy); locally advanced — definitive chemoradiation (cisplatin + RT); metastatic — pembrolizumab if PD-L1+ (KEYNOTE-158 cohort). Vaginal SCC managed similarly with RT-based approaches (anatomic constraints limit surgical options).

Utilisé par

Algorithmes

Maladie

Indication

Signal d’alerte

Sources